Tushar Srivastava is a health economist and decision modeller with extensive experience in statistical analyses. He has authored a handbook in Mathematics and has been endorsed as a ‘Global Talent’ by the prestigious ‘The Royal Society, UK’. He holds a Master of Science (M.Sc.) in Statistics and Computing from Banaras Hindu University and a Bachelor of Science (Hons.) in Mathematics from Delhi University.

Throughout his career, Tushar has worked in multiple disease areas, including oncology, CVD, infectious diseases, rare-diseases such as Fabry disease, ulcerative colitis, Crohn’s disease, and multiple sclerosis. He has extensive experience of product launch in countries in Europe, the United States, Latin America, and Australia.

Tushar is an expert in different modelling techniques including cost-effectiveness modelling, budget impact modelling, simulation modelling, statistical modelling, and evidence synthesis. He also has a good experience in statistical analyses, including survival analysis and health-related quality of life data analysis from clinical trials.

Recently, Tushar has contributed to several publications, and his latest research includes “Estimation of Transition Probabilities for State-Transition Models- A Review of NICE Appraisals", "Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia", and "Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach".

In his free time, Tushar enjoys playing badminton, jogging, and meditating.